X-82

AssetAlso called X-82 tablets

Dual inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor kinases

Stage
Phase 2, discontinued
Modality
Small molecule
Target
PDGFRB
9
Indications
3
Trials
1
Developer

Trial NCT02348359 terminated on Jan 12, 2018: Interim analysis found study had achieved primary objective. No trial still running and nothing reported since. clinicaltrials.gov

Indications

9

6 more

In the full profile

  • Target and mechanism5
  • Owner and partners1
  • Trials3
  • Evidence for its targets5
  • Competitors12

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets